Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder

Stephen R. Wisniewski, Chi Chang Chen, Edward Kim, Hong J. Kan, Zhenchao Guo, Berit X. Carlson, Quynh Van Tran, Andrei Pikalov

Research output: Contribution to journalArticle

Abstract

Objective: This study quantified the overall merit of adjunctive aripiprazole in major depressive disorder (MDD). Methods: Global benefit-risk (GBR) analysis quantified the benefit and risk differences between adjunctive aripiprazole and antidepressant (ADT) monotherapy. Three hundred and fifty six patients receiving ADT monotherapy and 366 patients receiving ADT and adjunctive aripiprazole (2-20 mg/day) were included. Efficacy measures included the Montgomery-A° sberg depression rating scale (MADRS) Total score response (≥50% reduction) and remission (response plus Total score≤10). Treatment-emergent adverse events were classified by severity. GBR ratio measures evaluated the relative benefit of adjunctive aripiprazole. Logistic regression models tested the effect of adjunctive aripiprazole on GBR and were used to identify predictors of net benefit and potential factors affecting the adjunctive aripiprazole treatment effect. Results: For MADRS-defined response and remission, the relative gain of adjunctive aripiprazole versus ADT monotherapy was 1.46 (p=0.044) and 1.43 ( p=0.085), respectively. Gender, current escitalopram, duration of current episode, and baseline body mass index are potential factors affecting the adjunctive aripiprazole treatment effect. Conclusions: Compared with ADT monotherapy, adjunctive aripiprazole was associated with an improved benefit-risk profile in MDD.

Original languageEnglish (US)
Pages (from-to)965-972
Number of pages8
JournalPharmacoepidemiology and Drug Safety
Volume18
Issue number10
DOIs
StatePublished - 2009

Keywords

  • Aripiprazole
  • Clinical advantage
  • Major depressive disorder

ASJC Scopus subject areas

  • Epidemiology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder'. Together they form a unique fingerprint.

  • Cite this

    Wisniewski, S. R., Chen, C. C., Kim, E., Kan, H. J., Guo, Z., Carlson, B. X., Tran, Q. V., & Pikalov, A. (2009). Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder. Pharmacoepidemiology and Drug Safety, 18(10), 965-972. https://doi.org/10.1002/pds.1805